| Company | Product | Description | Indication | Status |
| Affimed NV, of Heidelberg, Germany | AFM-13 | CD30- and CD16A-binding innate cell engager | T-cell lymphoma | FDA granted orphan drug designation |
| Applied Therapeutics Inc., of New York | AT-001 | Aldose reductase inhibitor | COVID-19 | IND opened with FDA for multiple investigator-initiated studies |
| Celularity Inc., of Warren, N.J. | CYNK-001 | Placenta-derived natural killer cell therapy | COVID-19 | FDA cleared the IND for a phase I/II trial |
| Fera Pharmaceuticals LLC, of New York, and Nicox SA, of Sophia Antipolis, France | Naproxcinod | Cyclooxygenase-inhibiting, nitric oxide-donating naproxen | Sickle cell disease | Applied for orphan drug designation with the FDA |
| Pfizer Inc., of New York | Ruxience (rituximab) | Biosimilar to Mabthera | Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris | Approved by the European Commission |
| Pharmamar SA, of Madrid | Aplidin (plitidepsin) | Cyclodepsipeptide | COVID-19 pneumonia | Submitted trial protocol for the Aplicov study to the Spanish Medicines and Healthcare Products Agency |
| Seattle Genetics Inc., of Bothell, Wash. | Padcev (enfortumab vedotin-ejfv) | Antibody-drug conjugate targeting Nectin-4 |